Research

Melanotan-1

A synthetic analogue of α-melanocyte-stimulating hormone, with two amino acid substitutions that make it far more stable than the natural hormone.

Also published as: Afamelanotide · Scenesse · [Nle4-D-Phe7]-α-MSH

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

What is being investigated

Directions the published work points at, and how far each has actually got. These are open questions, not established effects: most of what looks promising in cells does not replicate in animals, and most of what works in animals does not work in people. Nothing here is a claim about what this compound does for anyone.

  1. Photoprotection in erythropoietic protoporphyria

    The indication it is authorised in, on randomised evidence of pain-free time in direct sunlight. That authorisation covers a specific implant formulation, not this material.

    Human trials

  2. Eumelanin production without UV exposure

    The mechanism underneath: driving the darker, UV-absorbing pigment through MC1R rather than through sun damage. Measured directly in the trial work.

    Human trials

  3. Vitiligo and other photosensitivity disorders

    Studied in combination with narrowband UVB phototherapy for repigmentation, and in other light-sensitivity conditions. Smaller and less settled than the authorised indication.

    Human trials

Published research

Every reference below was checked against the published record before being listed, with the model each study used.

  1. Langendonk et al. (2015)New England Journal of Medicine · 373(1):48–59

    Reported a median 69.4 pain-free hours in direct sunlight versus 40.8 on placebo, in participants with erythropoietic protoporphyria.

    human, randomised controlled Source

Further reading

Longer articles on handling, analysis and what the published work reports.

All compounds